Hoya (TSE:7741) Stock After New FDA Clearance Weighing Rich Valuation Against Growth Potential

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge.

FDA clearance puts HOYA (TSE:7741) endoscopy devices in focus

HOYA (TSE:7741) has received US FDA clearance for new PENTAX Medical i20c Video Endoscope models, enabling use in US gastrointestinal endoscopy and drawing fresh attention to the stock's medical device exposure.

See our latest analysis for HOYA.

The FDA news lands after a mixed period for the stock, with the share price at ¥26,420, a 1-day share price return of 3.0%, a 30-day share price return down 5.7%, and a 1-year total shareholder return of 60.6%, which points to stronger longer term momentum.

If this kind of healthcare catalyst has your attention, it could be a good moment to see what else is moving in medical technology and related fields via the 7 healthcare AI stocks

With HOYA posting a 60.6% 1 year total return and trading at a discount to the average analyst price target, the key question now is whether the latest FDA clearance leaves upside on the table or whether the market is already pricing in future growth.

Price-to-earnings of 35x: Is it justified?

On a P/E of 35x, HOYA is pricing in a richer earnings tag than many peers, even after the strong 1 year total return and the recent FDA catalyst.

The P/E multiple compares the current share price with earnings per share, and for a profitable med-tech company like HOYA it reflects what investors are willing to pay for each unit of current earnings.

Here, the market is attaching a higher earnings multiple than both the peer group average of 25.5x and the Japan medical equipment industry average of 14.9x. It also sits above an estimated fair P/E of 27.4x that the market could potentially move closer to if expectations cool.

Explore the SWS fair ratio for HOYA

Result: Price-to-earnings of 35x (OVERVALUED).

However, higher expectations around the 35x P/E, along with any setback in medical device approvals or adoption, could quickly challenge the current optimism around HOYA.

Find out about the key risks to this HOYA narrative.

Another view using the SWS DCF model

The SWS DCF model points in the same direction as the rich 35x P/E. With the stock at ¥26,420 and an estimated future cash flow value of ¥22,878.87, HOYA also screens as overvalued here. This raises a practical question for you: how much of that premium feels comfortable?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day ( check out HOYA for example ). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 17 high quality undervalued stocks . If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.